Phase 2, multicenter, open-label study of tigatuzumab (CS-1008), a humanized monoclonal antibody targeting death receptor 5, in combination with gemcitabine in chemotherapy-naive patients with unresectable or metastatic pancreatic cancer

Andres Forero-Torres1, Jeffrey R. Infante2, David Waterhouse3, Lucas Wong4, Selwyn Vickers5, Edward Arrowsmith6, Aiwu Ruth He7, Lowell Hart8, David Trent9, James Wade10, Xiaoping Jin11, Qiang Wang11, TaShara Austin11, Michael Rosen11, Robert Beckman11, Reinhard von Roemeling11, Jonathan Greenberg11 & Mansoor Saleh12

1University of Alabama at Birmingham, Birmingham, Alabama
2Sarah Cannon Research Institute/Tennessee Oncology, PLLC, Nashville, Tennessee
3Oncology Hematology Care Clinical Trials, Cincinnati, Ohio
4Scott and White Hospital, Temple, Texas
5University of Minnesota, Minneapolis, Minnesota
6Chattanooga Oncology and Hematology Associates, Chattanooga, Tennessee
7Lombardi Comprehensive Cancer Center, Georgetown University, Washington, District of Columbia
8Florida Cancer Specialists, Fort Meyers, Florida
9Virginia Cancer Institute, Richmond, Virginia
10Decatur Memorial Hospital, Cancer Care Institute, Decatur, Illinois
11Daiichi-Sankyo Pharma Development, Edison, New Jersey
12Georgia Cancer Specialists, Atlanta, Georgia

Keywords
Monoclonal antibodies, pancreatic cancer, phase 2, tigatuzumab, TNF-related apoptosis-inducing ligand

Abstract
Tigatuzumab is the humanized version of the agonistic murine monoclonal antibody TRA-8 that binds to the death receptor 5 and induces apoptosis of human cancer cell lines via the caspase cascade. The combination of tigatuzumab and gemcitabine inhibits tumor growth in murine pancreatic xenografts. This phase 2 trial evaluated the efficacy of tigatuzumab combined with gemcitabine in 62 chemotherapy-naive patients with histologically or cytologically confirmed unresectable or metastatic pancreatic cancer. Patients received intravenous tigatuzumab (8 mg/kg loading dose followed by 3 mg/kg weekly) and gemcitabine (1000 mg/m² once weekly for 3 weeks followed by 1 week of rest) until progressive disease (PD) or unacceptable toxicity occurred. The primary end point was progression-free survival (PFS) at 16 weeks. Secondary end points included objective response rate (ORR) (complete responses plus partial responses), duration of response, and overall survival (OS). Safety of the combination was also evaluated. Mean duration of treatment was 18.48 weeks for tigatuzumab and 17.73 weeks for gemcitabine. The PFS rate at 16 weeks was 52.5% (95% confidence interval [CI], 39.3–64.1%). The ORR was 13.1%; 28 (45.9%) patients had stable disease and 14 (23%) patients had PD. Median PFS was 3.9 months (95% CI, 2.2–5.4 months). Median OS was 8.2 months (95% CI, 5.1–9.6 months). The most common adverse events related to tigatuzumab were nausea (35.5%), fatigue (32.3%), and peripheral edema (19.4%). Tigatuzumab combined with gemcitabine was well tolerated and may be clinically active for the treatment of chemotherapy-naive patients with unresectable or metastatic pancreatic cancer.
Introduction

Although pancreatic cancer accounts for approximately 3% of all the new cancer cases diagnosed in the United States, it is the fourth leading cause of all cancer deaths [1]. Despite multiple clinical trials with new anticancer agents and more aggressive surgical procedures, the 5-year disease-free survival is 2–9% for those patients diagnosed with locally advanced or metastatic disease [2]. Gemcitabine became the standard treatment of locally advanced or metastatic pancreatic cancer based on an increase in survival over fluorouracil [3]. In 2007, the United States Food and Drug Administration (FDA) approved gemcitabine in combination with erlotinib, a potent epidermal growth factor receptor tyrosine kinase inhibitor, for the treatment of chemotherapy-naive patients with locally advanced, inoperable, or metastatic pancreatic cancer based on the increase in survival by 23% (hazard ratio, 0.82) over gemcitabine alone [4]. However, the long-term survival for advanced disease remained extremely poor, with a median progression-free survival (PFS) at 16 weeks of 44% for patients treated with gemcitabine alone and 51% for those treated with gemcitabine in combination with other drugs (such as chemotherapy or erlotinib) and a median overall survival (OS) of only 6–8 months [3–10]. The FOLFIRINOX combination of chemotherapy (irinotecan, folinic acid, 5-fluorouracil, and oxaliplatin) showed improvement in PFS and OS compared with gemcitabine alone (PFS: 6.4 vs. 3.3 months; OS: 11.1 vs. 6.8 months, respectively) but there was a considerable increase in toxicity, which precludes the use of the regimen in all patients [11]. Most recently, the combination of gemcitabine and nab-paclitaxel improved OS and PFS compared with gemcitabine alone (OS: median 8.5 vs. 6.7 months and PFS: median 5.5 vs. 3.7 months, respectively) in the treatment of metastatic pancreatic cancer [12]. Nevertheless, there remains a need for new agents or combinations of agents.

Tumor necrosis factor (TNF)-related apoptosis-inducing ligand (TRAIL), a member of the TNF superfamily of cytokines, is a type 2 membrane protein that is expressed in the majority of normal tissues and can undergo protease cleavage, resulting in a soluble form able to bind to TRAIL death receptors (DRs) [13]. TRAIL induces apoptosis of cancer cells in vitro and has potent tumor activity against tumor xenografts of various cancers in vivo via DRs [13]. Although five receptors for TRAIL have been identified, only two of them (DR4 and DR5) are able to trigger apoptosis of tumor cells through activation of the extrinsic apoptotic pathway (caspase cascade mediated) [13–15]. Interestingly, the other three receptors lack a cytoplasmic death domain and do not mediate apoptosis [16]. High expression of DR5 is frequently observed in various human cancers including colorectal [17, 18], hepatic [19], breast [20], non–small cell lung [21], prostate [22], ovarian [20], and pancreatic [23] cancers.

Tigatuzumab (CS-1008) is the humanized version of the agonistic anti-DR5 murine monoclonal antibody TRA-8 [13–15]. It is composed of the complementarity determining region of the murine monoclonal antibody TRA-8 and the variable region framework and constant regions of human immunoglobulin IgG-1 mAb58’CL [23]. Tigatuzumab induces apoptosis after binding to DR5 in tumor cell lines, resulting in the death of targeted human cancer cells [23, 24]. Tigatuzumab has demonstrated potent in vitro cytotoxic activity against multiple DR5-positive human tumor cell lines, including pancreatic cell lines, and significant in vivo antitumor activity against human tumor xenografts in nude mice with minimal toxicity toward normal tissues [23, 25, 26]. A phase 1, single-agent, dose-escalation study of tigatuzumab in patients with relapsed or refractory carcinomas showed that tigatuzumab is well tolerated with no infusion reactions or grade 3/4 toxicity; the maximal tolerated dose was not reached [27]. In the study, 41% of the patients had stable disease (SD) for a prolonged period of time suggesting antitumor activity. Disease stabilization was observed in patients with hepatocellular carcinoma, carcinoma of the head and neck, colon carcinoma, and cholangiocarcinoma with the duration of stabilization ranging from 81 to 798 days.

The phase 2 study described in this report was designed to evaluate the efficacy of tigatuzumab administered in combination with gemcitabine to chemotherapy-naive patients diagnosed with unresectable or metastatic pancreatic cancer.

Material and Methods

Patients

Male and female patients older than 18 years of age with histologically or cytologically confirmed unresectable or metastatic pancreatic cancer that were not previously treated with chemotherapy were enrolled in this clinical trial. All patients had measurable disease at baseline per Response Evaluation Criteria in Solid Tumors (RECIST Version 1.0; http://www.eortc.be/recist/), had a Karnofsky Performance Status (KPS) score ≥60 [28], and had adequate organ and bone marrow function as evidenced by: hemoglobin ≥9.0 g/dL; absolute neutrophil count ≥1.5 × 10^9/L; a platelet count ≥100 × 10^9/L; serum creatinine <1.5 mg/dL or creatinine clearance >60 mL/min; aspartate aminotransferase, alanine aminotransferase, and alkaline phosphatase ≤2.5 × the upper limit of normal.
was 12 used from study treatment. The planned study duration in patients with objective response or SD until progression (every 8 weeks). Treatment continued without interruption in patients with objective response (i.e., CR or PR) to the date of the first documentation of PD. An unknown response was defined as no tumor assessment after the first infusion of study drug and no recorded clinical disease progression.

Treatment-emergent adverse events (TEAEs) were collected and reported from the time of the first dose administration of the study drug to 30 days after the last dose administration. Toxicities were graded according to National Cancer Institute Common Terminology Criteria for Adverse events, Version 3.0.

Human anti-human antibody measurements (HAHA) were conducted before the infusion of tigatuzumab, at 4 and 8 weeks after the tigatuzumab infusion and every 8 weeks thereafter during active treatment, and whenever possible, 3 months after the end of treatment. A HAHA measurement was also taken at the time when a patient withdrew from the study. The HAHA analysis was performed using a qualitative solid-phase assay designed to detect anti-CS-1008 antibodies in human serum. In this assay, anti-CS-1008 antibodies were captured by CS-1008 bound on a microtiter plate. Captured anti-CS-1008 antibodies were detected with biotin-labeled CS-1008 followed by a commercial streptavidin-horseradish peroxidase (HRP) conjugate. Tetramethylbenzidine was used as the substrate to produce colorimetric optical density. If a sample response was above the established cut-off point (0.040), it was considered potentially positive for the presence of anti-CS-1008 antibodies and further testing was performed. A response below the cut-off point classified the sample as negative for anti-CS-1008 antibodies.

**Statistical analysis**

The primary end point of the study was PFS at 16 weeks. Based on published data, the 16-week PFS rate for single-agent gemcitabine was approximately 44%, while it was approximately 51% for the gemcitabine combinations [3–10]. Thus, with 60 patients treated in this trial, the distance between the point estimate and the 95% one-sided lower (upper) bound for the 16-week PFS rate was approximately 10% if the estimate was around 50%. Standard survival analyses using a Kaplan–Meier approach were performed for PFS and OS. The best overall tumor response was summarized. Descriptive statistics (i.e., mean, standard deviation, median, minimum, and maximum) were used in the summary of continuous variables from this trial. Frequency and percentage of observed levels were reported for categorical measures. The per protocol analysis set for efficacy and safety included patients who received at least one dose of tigatuzumab and gemcitabine and who had no major protocol violations.
Results

Patients

Between August 2007 and August 2010, a total of 65 patients were enrolled in the study; of these, 61 were included in the efficacy analysis and 62 in the safety analysis only (three patients failed to meet entry criteria and did not receive any treatment per protocol and one patient failed to meet the inclusion criteria but received the study combination). Baseline characteristics of the 61 patients included in the safety and efficacy analysis are listed in Table 1. Thirty-six patients were men and 25 women, with a median age of 61 years (range, 36–78) (Table 1). Fifty-three (87%) patients had metastatic disease, while only 8 (13%) were locally advanced and were not surgical candidates. Patients were predominantly white (95%). The median number of days from diagnosis to initiation of protocol therapy was 22 (range, 4–149).

The majority of patients had a KPS \( \geq 80 \) (KPS 80–90, 74%; KPS 100, 10%). No patient had received prior chemotherapy.

Efficacy

Sixty-one patients were included in the analyses of efficacy and these results are shown in Table 2. Eleven (18%) patients discontinued study participation before the first scheduled evaluation: two patients withdrew consent (one due to severe nausea, one for nonmedical reasons), four patients had a rapid disease progression, and five patients had serious medical conditions including: stroke (one patient, unrelated), sepsis due to Clostridium difficile colitis (one patient, unrelated), perforated bowel (one patient, possibly related to gemcitabine in the opinion of the investigator), and cardiac conditions (two patients, one of them possibly related to gemcitabine in the opinion of the investigator).

The PFS rate was 52.5% (95% confidence interval [CI], 39.3–64.1%) at 16 weeks, 34.4% (95% CI, 22.9–46.3%) at 6 months, 21.3% (95% CI, 12.1–32.2%) at 9 months, and 13.1% (95% CI, 6.1–22.8%) at 1 year. As seen in Figures 1 and 2, the median PFS was 3.9 months (95% CI, 2.2–5.4 months), and the median OS was 8.2 months (95% CI, 5.1–9.6 months), respectively. The OS rate was 55.7% (95% CI, 42.4–67.1%) at 6 months, 24.6% at 1 year (95% CI, 14.7–35.9%), and 13.1% at 15 months (95% CI, 6.1–22.8%). The ORR (CR + PR) was 13.1%.

Table 1. Demographic and baseline characteristics of all study patients who received tigatuzumab in combination with gemcitabine for metastatic pancreatic cancer and met the inclusion criteria (per protocol analysis set).

| Category                          | All patients \((N = 61)\) |
|-----------------------------------|---------------------------|
| Median age (years) \(\text{range}\) | 60.6 (36–78)              |
| Gender, \(n\) (\%)                |                           |
| Male                              | 36 (59)                   |
| Female                            | 25 (41)                   |
| Race, \(n\)                       |                           |
| White                             | 58 (95.1)                 |
| Black or African American         | 2 (3.3)                   |
| White, Black, or African American | 1 (1.6)                   |
| Median height (cm) \(\text{range}\) | 167.60 (151.1–190.5)      |
| Median weight (kg) \(\text{range}\) | 79.10 (44.5–129.1)        |
| Tumor stage at diagnosis, \(n\) (\%) | 53 (86.9)               |
| Stage IV                          | 8 (13.1)                  |
| Time from diagnosis of pancreatic cancer to study treatment (days) | 31.6 |
| Mean                              |                           |
| Standard deviation                | 25.25                     |
| Median                            | 22.0                      |
| Range                             | 4–149                     |
| Karnofsky Performance Status (KPS score, \(n\) (\%)) | 2 (3.3) |
| 60                                |                           |
| 70                                | 7 (11.5)                  |
| 80                                | 19 (31.1)                 |
| 90                                | 26 (42.6)                 |
| 100                               | 6 (9.8)                   |
| >90                               | 32 (52.5)                 |
| Unknown                           | 1                         |

Table 2. Best overall tumor response for patients who received tigatuzumab in combination with gemcitabine for metastatic pancreatic cancer and met the inclusion criteria (per protocol analysis set).1

| Category                        | All patients \((N = 61)\) |
|---------------------------------|---------------------------|
| CR                              |                           |
| \(N\) (%)                       | 0                         |
| 95% CI                          | 0.0; 5.9                  |
| PR                              |                           |
| \(N\) (%)                       | 8 (13.1%)                 |
| 95% CI                          | 5.8; 24.2                 |
| Median duration of response days per patient | 309 days (112, 562, 109, 421) |
| Objective response (CR or PR)   |                           |
| \(N\) (%)                       | 8 (13.1%)                 |
| 95% CI                          | 5.8; 24.2                 |
| SD                              |                           |
| \(N\) (%)                       | 28 (45.9%)                |
| 95% CI                          | 33.1; 59.2                |
| PD                              |                           |
| \(N\) (%)                       | 14 (23.0%)                |
| 95% CI                          | 13.2; 35.5                |
| Inevaluable                     |                           |
| \(N\) (%)                       | 11 (18.0%)                |
| 95% CI                          | 9.4; 30.0                 |

For all subjects, mean duration of treatment was 18.48 (range, 1–88.3) weeks for tigatuzumab and 17.73 (range, 1.0–87.3) weeks for gemcitabine. CR, complete response; PR, partial response; SD, stable disease; PD, progressive disease.

1Treatment was discontinued at disease progression.
(eight patients, all PR). In addition, 28 (45.9%) patients had SD, and 14 (23%) patients had PD. The median duration of response for those patients that achieved a PR was 309 days (mean, 280.4; range, 55–562 days; Table 2).

**Safety and tolerability**

As described previously, 62 patients, who received at least one dose of the agents used in the trial, were included in the safety analysis of the study. For all subjects, the mean duration of treatment was 18.48 weeks for tigatuzumab and 17.73 weeks for gemcitabine. Tigatuzumab dose was not modified in the trial. Table 3 illustrates the adverse events observed in at least 20% of the patients independent of the relation to protocol medications. As can be seen in the table, the majority of the adverse events were grade 1, 2, and 3 (75.8%); only four grade 4 adverse events were seen and no grade 5 adverse events were observed. Sixty-nine percent of the adverse events were reported by the investigators as possibly related to tigatuzumab and 87.1% were reported as possibly related to gemcitabine. The most common adverse events were nausea (75.8%), fatigue (69.4%), abdominal pain (51.6%), constipation (50%), fever (48.4%) peripheral edema (40.3%), diarrhea (38.7%), anorexia (35.5%), and anemia (33.9%).

Thirty-five (56.5%) patients experienced serious adverse events while on therapy; nine were related to the protocol medications and 26 related to disease. Of the nine treatment-related events, one was reported by the investigator as tigatuzumab related (peripheral edema) and the other...
eight were considered by investigators as possibly related to gemcitabine (pleural effusion, urinary tract infection, pneumonia, anemia [two patients], hemolytic uremic syndrome with bowel perforation, heart failure, and vomiting). Six (9.7%) patients died during the study; one case was considered by the investigator as possibly related to gemcitabine and unrelated to tigatuzumab (congestive heart failure); one case was assessed as unrelated to tigatuzumab (causality assessment for gemcitabine not reported) while the other four deaths were considered secondary to disease progression.

Thirty-three (53.2%) patients discontinued treatment due to disease progression, 13 (21.0%) due to adverse events, three (4.8%) withdrew consent, and 13 (21.0%) discontinued for other reasons. Of the patients who discontinued study therapy due to an adverse event, one was possibly related to tigatuzumab (peripheral edema) while two were possibly related to gemcitabine (hemolytic uremic syndrome, congestive cardiac failure). None of the patients developed human antihuman antibodies during the trial.

Discussion

Despite advances in the treatment of cancer over the last decade, pancreatic cancer continues to have a poor prognosis due to the lack of effective agents; thus, new therapeutic strategies are needed. In this phase 2 study, a total of 62 untreated patients with unresectable or metastatic pancreatic cancer were treated with the standard therapeutic agent gemcitabine combined with tigatuzumab, based on encouraging preclinical data that showed a synergistic effect between the chemotherapy agent and the monoclonal antibody [23, 25, 26], and based on the clinical safety demonstrated by the monoclonal antibody in the phase 1 clinical trial [27]. For all patients, the mean duration of treatment was 18.48 weeks for tigatuzumab and 17.73 weeks for gemcitabine.

The primary end point of this study, PFS rate at 16 weeks, was 52.5%, which is similar to that seen in published studies using gemcitabine alone (median 44%; range 33–51) or in combination with other agents including the FDA-approved agent erlotinib (median 51%; range 45–60) [4–10]. In addition, our study demonstrated a median OS of 8.2 months, which is comparable to that seen in previous studies of patients with advanced pancreatic cancer treated with gemcitabine alone or gemcitabine plus other agents; with a median OS of 3.6–6.8 months and 3.8–11.1 months, respectively [3, 4, 6, 11, 29]. Of note, in the two pivotal gemcitabine trials, the OS was 3.9 [30] and 5.7 months [3], while OS was 6.4 months in the pivotal trial of gemcitabine plus erlotinib [4]. In the FOLFIRINOX trial, median OS was 11.1 months versus 6.8 months with gemcitabine alone; however, FOLFIRINOX was associated with increased toxicity [11] and in the recent phase 3 MPACT trial, median OS was 8.5 months with nab-paclitaxel plus gemcitabine [12].

Table 3. Summary of treatment-emergent adverse events (TEAEs) and serious TEAEs experienced by >20% of subjects who received tigatuzumab in combination with gemcitabine for metastatic pancreatic cancer (safety analysis set; n = 62).

| Adverse events seen in more than 20% of the patients, n (%) |
|------------------------------------------------------------|
| Toxicity grade                                            |
| All | 1 | 2   | 3    | 4    | 5    |
| Nausea | 47 (75.8) | 22 (35.5) | 21 (33.9) | 4 (6.5) | 0 0 0 |
| Fatigue  | 43 (69.4) | 13 (21) | 24 (38.7) | 6 (9.7) | 0 0 0 |
| Abdominal pain | 32 (51.6) | 15 (24.2) | 8 (12.9) | 8 (12.9) | 1 (1.6) 0 0 |
| Constipation | 31 (50) | 20 (32.3) | 9 (14.5) | 2 (3.2) | 0 0 0 |
| Fever | 30 (48.4) | 19 (30.6) | 9 (14.5) | 2 (3.2) | 0 0 0 |
| Peripheral edema | 25 (40.3) | 16 (25.8) | 8 (12.9) | 1 (1.6) | 0 0 0 |
| Diarrhea  | 24 (38.7) | 17 (27.4) | 5 (8.1) | 2 (3.2) | 0 0 0 |
| Anorexia  | 22 (35.5) | 10 (16.1) | 12 (19.3) | 0 0 0 |
| Anemia | 21 (33.9) | 7 (11.3) | 8 (12.9) | 5 (8.1) | 1 (1.6) 0 0 |
| Anxiety | 18 (29) | 10 (16.1) | 7 (11.3) | 1 (1.6) | 0 0 0 |
| Asthenia | 17 (27.4) | 6 (9.7) | 8 (12.9) | 3 (4.8) | 0 0 0 |
| Dyspnea | 16 (25.8) | 7 (11.3) | 1 (1.6) | 6 (9.7) | 2 (3.2) 0 0 |
| Back pain | 15 (24.2) | 7 (11.3) | 6 (9.7) | 2 (3.2) | 0 0 0 |
| Neutropenia | 15 (24.2) | 2 (3.2) | 2 (3.2) | 11 (17.7) | 0 0 0 |
| Insomnia | 15 (24.2) | 12 (19.3) | 3 (4.8) | 0 0 0 0 0 |
| Headache | 14 (22.6) | 9 (14.5) | 4 (6.5) | 1 (1.6) | 0 0 0 |
| Thrombocytopenia | 14 (22.6) | 5 (8.1) | 4 (6.5) | 5 (8.1) | 0 0 0 |
| Dehydration | 14 (22.6) | 2 (3.2) | 5 (8.1) | 7 (11.3) | 0 0 0 |
| Weight loss | 13 (21) | 9 (14.5) | 4 (6.5) | 0 0 0 |
Other efficacy parameters observed in this study were also comparable with previous studies using gemcitabine alone or in combination, including percent of patients with PR or SD and duration of response [3, 4, 6, 11, 29, 30]. Thus, the numeric trends described in the current study compared with historical data observed with gemcitabine alone suggest a possible contribution of tigatuzumab to the antitumor efficacy of gemcitabine. However, the current study represents a single-arm trial, and no definitive conclusions can be drawn regarding the contribution of tigatuzumab to the observed ORR, PFS, or OS data.

Tigatuzumab was safe and well tolerated when administered in combination with gemcitabine. The most commonly reported adverse events were fatigue, vomiting, abdominal pain, and pyrexia, which are typical of disease progression in this patient population and are similar to those reported in previous studies of gemcitabine [3, 4, 29]. The majority of tigatuzumab-related adverse events were grade 1 or grade 2. No patient had a grade 4 or grade 5 adverse event that was related to tigatuzumab treatment. Only one patient had a serious adverse event (peripheral edema) that was considered by the investigator to be related to tigatuzumab treatment.

In conclusion, data from this phase 2 clinical trial show that the combination of tigatuzumab and gemcitabine is well tolerated and may be clinically active in the treatment of chemotherapy-naive patients with unresectable or metastatic pancreatic cancer.

Acknowledgments
We thank Mendel Jansen, Daiichi-Sankyo Ltd., and Zenta Tsuchihashi, Daiichi Sankyo, Inc. for their careful review of the manuscript. This work was supported with funding from Daiichi Sankyo Pharma Development, a division of Daiichi Sankyo, Inc. Editorial assistance was provided by Mark English, Ph.D., Yamini Khirwadkar, Ph.D., and Caroline Allinson of PAREXEL Inc. and was funded by Daiichi Sankyo Pharma Development.

Conflict of Interest
A. Forero-Torres and L. Hart disclose research support from Daiichi Sankyo to their institutions. X. Jin, Q. Wang, and R. Beckman are full-time employees of Daiichi Sankyo Pharma Development. R. Beckman is also a stockholder in DSPD and in Johnson and Jin holds stock in Daiichi Sankyo. R. von Roemeling, M. Rosen, and J. Greenberg are full-time employees of Daiichi Sankyo and J. Greenberg also holds stock in Daiichi Sankyo. T. Austin was a full-time employee of Daiichi Sankyo at the time that the study was conducted. All other authors have no conflicts to disclose.

References
1. Siegel, R., D. Naishadham, and A. Jemal. 2012. Cancer statistics, 2012. CA Cancer J. Clin. 1:10–29.
2. National Cancer Institute. 2011. SEER stat fact sheets: pancreas. Available at http://seer.cancer.gov/statfacts/html/pancreas.html (accessed 2 April 2012).
3. Burris, H. A., III, M. J. Moore, J. Andersen, M. R. Green, M. L. Rothenberg, M. R. Modiano, et al. 1997. Improvements in survival and clinical benefit with gemcitabine as first-line therapy for patients with advanced pancreas cancer: a randomized trial. J. Clin. Oncol. 6:2403–2413.
4. Moore, M. J., D. Goldstein, J. Hamm, A. Figer, J. R. Hecht, S. Gallinger, et al. 2007. Erlotinib plus gemcitabine compared with gemcitabine alone in patients with advanced pancreatic cancer: a phase III trial of the National Cancer Institute of Canada Clinical Trials Group. J. Clin. Oncol. 15:1960–1966.
5. Berlin, J. D., P. Catalano, J. P. Thomas, J. W. Kugler, D. G. Haller, and A. B. Benson III. 2002. Phase III study of gemcitabine in combination with fluorouracil versus gemcitabine alone in patients with advanced pancreatic carcinoma: Eastern Cooperative Oncology Group Trial E2297. J. Clin. Oncol. 15:3270–3275.
6. Heinemann, V., D. Quietzsch, F. Gieseler, M. Sonnermann, H. Schonekas, A. Rost, et al. 2006. Randomized phase III trial of gemcitabine plus cisplatin compared with gemcitabine alone in advanced pancreatic cancer. J. Clin. Oncol. 24:3946–3952.
7. Herrmann, R., G. Bodoky, T. Ruhstaller, B. Glimelius, E. Bajetta, J. Schuller, et al. 2007. Gemcitabine plus capcitabine compared with gemcitabine alone in advanced pancreatic cancer: a randomized, multicenter, phase III trial of the Swiss Group for Clinical Cancer Research and the Central European Cooperative Oncology Group. J. Clin. Oncol. 16:2212–2217.
8. Louvet, C., R. Labianca, P. Hammel, G. Lledo, M. G. Zampino, T. Andre, et al. 2005. Gemcitabine in combination with oxaliplatin compared with gemcitabine alone in locally advanced or metastatic pancreatic cancer: results of a GERCOR and GISCAD phase III trial. J. Clin. Oncol. 15:3509–3516.
9. Riess, H., A. Helm, I. Niedergethmann, M. Schmidt-Wolf, M. Moik, C. Hammer, et al. 2005. A randomised, prospective, multicenter, phase II trial of gemcitabine, 5-fluorouracil (5-FU), folinic acid vs. gemcitabine alone in patients with advanced pancreatic cancer. J. Clin. Oncol. 16(5Pt. I of II, June Suppl.):Abstract no. 4009.
10. Rocha Lima, C. M., M. R. Green, R. Rotche, W. H. Miller Jr., G. M. Jeffrey, L. A. Cisar, et al. 2004. Irinotecan plus gemcitabine results in no survival advantage compared with gemcitabine monotherapy in patients with locally advanced or metastatic pancreatic cancer despite increased tumor response rate. J. Clin. Oncol. 18:3776–3783.
11. Conroy, T., F. Desseigne, M. Ychou, O. Bouche, R. Guimbaud, Y. Becouarn, et al. 2011. FOLFIRINOX versus gemcitabine for metastatic pancreatic cancer. N. Engl. J. Med. 19:1817–1825.

12. Von Hoff, D. D., T. J. Ervin, F. P. Arena, G. Chiorean, J. R. Infante, M. J. Moore, et al. 2012. Randomized phase III study of weekly nab-paclitaxel plus gemcitabine versus gemcitabine alone in patients with metastatic adenocarcinoma of the pancreas (MPACT). J. Clin. Oncol. 30(Suppl. 34): Abstract no. LBA148.

13. Ashkenazi, A. 2008. Directing cancer cells to self-destruct with pro-apoptotic receptor agonists. Nat. Rev. Drug. Discov. 12:1001–1012.

14. Debatin, K. M., and P. H. Krammer. 2004. Death receptors in chemotherapy and cancer. Oncogene 16:2950–2966.

15. Debatin, K. M. 2004. Apoptosis pathways in cancer and cancer therapy. Cancer Immunol. Immunother. 3:153–159.

16. Wiezorek, J., P. Holland, and J. Graves. 2010. Death receptor agonists as a targeted therapy for cancer. Clin. Cancer Res. 6:1701–1708.

17. Koornstra, J. J., M. Jalving, F. E. Rijcken, J. Westra, N. Zwart, H. Hollema, et al. 2005. Expression of tumour necrosis factor-related apoptosis-inducing ligand death receptors in sporadic and hereditary colorectal tumours: potential targets for apoptosis induction. Eur. J. Cancer 8:1195–1202.

18. Perraud, A., H. Akil, M. Nouaille, D. Petit, F. Labrousse, M. O. Jauberteau, et al. 2011. Expression of p53 and DR5 in normal and malignant tissues of colorectal cancer: correlation with advanced stages. Oncol. Rep. 5:1091–1097.

19. Chen, X. P., S. Q. He, H. P. Wang, Y. Z. Zhao, and W. G. Zhang. 2003. Expression of TNF-related apoptosis-inducing ligand receptors and antitumor tumor effects of TNF-related apoptosis-inducing ligand in human hepatocellular carcinoma. World J. Gastroenterol. 11:2433–2440.

20. Dong, H. P., L. Kleinberg, I. Silins, V. A. Florenes, C. G. Trope, B. Risberg, et al. 2008. Death receptor expression is associated with poor response to chemotherapy and shorter survival in metastatic ovarian carcinoma. Cancer 1:84–93.

21. Spiere, D. C., E. G. de Vries, W. Timens, H. J. Groen, H. M. Boezen, and S. de Jong. 2003. Expression of TRAIL and TRAIL death receptors in stage III non-small cell lung cancer tumors. Clin. Cancer Res. 9:3397–3405.

22. Hesry, V., C. Piquet-Pellorce, M. Travert, L. Donaghy, B. Jegou, J. J. Patard, et al. 2006. Sensitivity of prostate cells to TRAIL-induced apoptosis increases with tumor progression: DR5 and caspase 8 are key players. Prostate 9:987–995.

23. Yada, A., M. Yazawa, S. Ishida, H. Yoshida, K. Ichikawa, S. Kurakata, et al. 2008. A novel humanized anti-human death receptor 5 antibody CS-1008 induces apoptosis in tumor cells without toxicity in hepatocytes. Ann. Oncol. 6:1060–1067.

24. Ichikawa, K., W. Liu, L. Zhao, Z. Wang, D. Liu, T. Ohtsu, et al. 2001. Tumoricidal activity of a novel anti-human DR5 monoclonal antibody without hepatocyte cytotoxicity. Nat. Med. 8:954–960.

25. DeRosier, L. C., Z. Q. Huang, J. C. Sellers, D. J. Buchsbaum, and S. M. Vickers. 2006. Treatment with gemcitabine and TRA-8 anti-death receptor-5 mAb reduces pancreatic adenocarcinoma cell viability in vitro and growth in vivo. J. Gastrointest. Surg. 9:1291–1300.

26. DeRosier, L. C., S. M. Vickers, K. R. Zinn, Z. Huang, W. Wang, W. E. Grizzle, et al. 2007. TRA-8 anti-DR5 monoclonal antibody and gemcitabine induce apoptosis and inhibit radiologically validated orthotopic pancreatic tumor growth. Mol. Cancer Ther. 12(Pt. 1):3198–3207.

27. Forero-Torres, A., J. Shah, T. Wood, J. Posey, R. Carlisle, C. Copigneaux, et al. 2010. Phase I trial of weekly tigatuzumab, an agonistic humanized monoclonal antibody targeting death receptor 5 (DR5). Cancer Biother. Radiopharm. 1:13–19.

28. Karnofsky, D. A., W. H. Abelmann, L. F. Craver, and J. H. Burchenal. 1948. The use of nitrogen mustards in the palliative treatment of carcinoma: with particular reference to bronchogenic carcinoma. Cancer 1:634–656.

29. Van Cutsem, E., H. van de Velde, P. Karasek, H. Oettle, W. L. Vervenne, A. Szawlowski, et al. 2004. Phase III trial of gemcitabine plus tipifarnib compared with gemcitabine plus placebo in advanced pancreatic cancer. J. Clin. Oncol. 8:1430–1438.

30. Rothenberg, M. L., M. J. Moore, M. C. Cripps, J. S. Andersen, R. K. Portenoy, H. A. Burris III, et al. 1996. A phase II trial of gemcitabine in patients with 5-FU-refractory pancreas cancer. Ann. Oncol. 4:347–353.